Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ergoferon in Acute Respiratory Viral Infections in Children
NCT03039621Phase 4Completed
- Sponsor
- Materia Medica Holding
- Start
- Oct 2016
- Primary completion
- Jan 2019
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 2
01
Overview
A Phase 4 trial of Ergoferon in acute respiratory viral infection (ARVI), sponsored by Materia Medica Holding. Started Oct 2016; status: completed.
02
Drugs
Ergoferon
03
Conditions
acute respiratory viral infection (ARVI)
Beyond the preview
Go deeper on NCT03039621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03039621.